Referring to the information, published at the news portal BNS, JSC Grindeks confirms that expansion of cooperation with the Latvian Institute of Organic Synthesis is being considered. With the aim to combine scientific work and the production of pharmaceuticals, JSC Grindeks would consider buying the Institute of Organic Synthesis, if such opportunity existed.
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. Product portfolio of Grindeks consists of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.
Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are: the Baltic States, Russia and other CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”.
Deputy Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083336, (+371) 26466681
Fax: (+371) 67083505